Microalbuminuria

Only 40% of Diabetes Patients Get Recommended Kidney Health Testing

Retrieved on: 
Wednesday, August 30, 2023
Blood pressure, Heart, NCQA, CMS, Healthcare Effectiveness Data and Information Set, KED, American Diabetes Association, Chronic kidney disease, Education, Face, HEDIS, Centers for Medicare & Medicaid Services, Microalbuminuria, Public, Health information management, EGFR, Glomerular filtration rate, Research, Mayo Clinic Proceedings, CMO, Kidney, Doctor of Philosophy, Quality, Medicare, National Committee, MD, Patient, NKF, Risk, Albuminuria, Quality assurance, National Kidney Foundation, Diagnosis, CKD, ADA, Kidney disease, National Committee for Quality Assurance, Pharmaceutical industry, Medical device, Dietary supplement, Diabetes

NEW YORK, Aug. 30, 2023 /PRNewswire/ -- Not enough diabetes patients are getting their recommended kidney health screenings, according to a new study by the National Kidney Foundation (NKF) and the National Committee for Quality Assurance (NCQA).

Key Points: 
  • NEW YORK, Aug. 30, 2023 /PRNewswire/ -- Not enough diabetes patients are getting their recommended kidney health screenings, according to a new study by the National Kidney Foundation (NKF) and the National Committee for Quality Assurance (NCQA).
  • "Kidney health testing is pivotal to ensuring timely diagnosis & equitable treatment of CKD," said Dr. Vassalotti, CMO
    According to new data published in Mayo Clinic Proceedings: Innovations, Quality & Outcomes journal, less than 40% of patients with diabetes have been recommended at least annual kidney health screening tests.
  • NKF is calling on health professionals to prioritize kidney health screening for individuals with diabetes which is pivotal to ensuring timely diagnosis and equitable treatment of CKD.
  • "Kidney health testing is pivotal to ensuring timely diagnosis and equitable treatment of CKD," added Joseph Vassalotti, MD, NKF Chief Medical Officer.

HealthVerity releases its expertly curated Chronic Kidney Disease Masterset to synchronize the science

Retrieved on: 
Tuesday, August 22, 2023
Glycated hemoglobin, Medicaid, Noise, Diabetes, Creatinine, EMR, Microalbuminuria, Research, Risk, RWD, Science, Hypertension, Medicare, Provider, HIV disease progression rates, Data, Patient, Body mass index, Mortality, Death, CKD, ICPE, Disease, Pharmaceutical industry

PHILADELPHIA, Aug. 22, 2023 /PRNewswire/ -- HealthVerity, the leader in synchronizing transformational technologies and real-world data (RWD) to advance the science, today announced the launch of the HealthVerity Chronic Kidney Disease (CKD) Masterset, an expertly curated dataset that synchronizes lab results, commercial, Medicare and Medicaid claims, and electronic medical records (EMRs) from the nation's largest healthcare and consumer data ecosystem. An addition to our growing suite of HealthVerity Mastersets, including the Provider Diversity Index 2023 edition and the Maternal Outcomes Masterset, the CKD Masterset compiles all CKD-relevant clinical attributes into one comprehensive, research-ready masterset, accelerating research by saving valuable time and resources.

Key Points: 
  • HealthVerity experts standardize and deduplicate the data, ensuring all of the most relevant CKD data points are included, without additional noise from RWD, providing a more concise, easy-to-use masterset.
  • "CKD is complicated by several comorbid conditions, such as diabetes, hypertension and heart disease," explained Reyna Klesh, vice president, data products and innovation at HealthVerity.
  • HealthVerity will continue to add to their Masterset Series, providing researchers speed to insights through expertly curated datasets that profile some of the most important diseases.
  • Book your meeting with the HealthVerity team at booth #402 in Halifax, Nova Scotia, August 23-27, 2023.

Signify Health Launches Chronic Kidney Disease Testing, Expands In-Home Diagnostic and Preventive Services Offering

Retrieved on: 
Tuesday, August 1, 2023
ESRD, Medicare Advantage, IHE, Kidney failure, KED, Centers for Medicare & Medicaid Services, Hospital, Microalbuminuria, Health, EGFR, Diagnosis, Glomerular filtration rate, Dialysis, CDC, Chronic kidney disease, Risk, Community service, Disease, QPP, United States Preventive Services Task Force, Mortality, Centers for Disease Control and Prevention timeline, CVS Health, Patient, MPH, CKD, NYSE, Urinalysis, Kidney, Pharmaceutical industry, DALLAS, Medicare, MD, Diabetes

DALLAS and NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Signify Health, a CVS Health company (NYSE: CVS), today announced the addition of a comprehensive in-home kidney health evaluation to its Diagnostic and Preventive Services offering. The new screenings expand Signify Health's suite of services designed to support the early detection, diagnosis, and management of some of the leading causes of morbidity and mortality among people covered under Medicare Advantage. 

Key Points: 
  • The expanded offering supports the early diagnosis and management of Chronic Kidney Disease (CKD), impacting an estimated 37 million U.S. adults, many undiagnosed
    DALLAS and NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Signify Health , a CVS Health company (NYSE: CVS), today announced the addition of a comprehensive in-home kidney health evaluation to its Diagnostic and Preventive Services offering .
  • Signify Health providers perform the kidney health evaluation as part of an In-home Health Evaluation (IHE), which is available at no additional cost to Medicare Advantage plan members.
  • "Chronic kidney disease is often underdiagnosed and, if not addressed, can lead to a need for dialysis or kidney transplant, especially for those who also have diabetes," said Heidi Schwarzwald, MD, MPH, Chief Medical Officer, Signify Health Home and Community Services.
  • The Centers for Disease Control (CDC) estimates that 37 million U.S. adults have Chronic Kidney Disease (CKD), most of whom are undiagnosed.

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Retrieved on: 
Tuesday, July 25, 2023
DNA, OCX, CSO, Microalbuminuria, Acute kidney injury, EGFR, Liver, Immunoglobulin A, Biomarker, DSA, Doctor of Philosophy, Medicare, IgA nephropathy, Nephrology, Kidney, MD, Patient, Physician, Kidney transplantation, Health, Pharmaceutical industry, Palmetto

IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced the publication of new data demonstrating VitaGraft Kidney’s novel ability to help physicians treat kidney transplant patients more precisely, quickly, and effectively. The test was able to distinguish between two prevalent causes of premature graft failure: biopsy-proven antibody-mediated rejection (ABMR) and recurrent IgA nephropathy (IgAN). This is the first publication investigating this application of VitaGraft’s donor-derived cell-free DNA (dd-cfDNA) diagnostic technology for kidney transplant patients. The data was published as a paper in the peer-reviewed journal Kidney International Reports.

Key Points: 
  • This is the first publication investigating this application of VitaGraft’s donor-derived cell-free DNA (dd-cfDNA) diagnostic technology for kidney transplant patients.
  • This ongoing prospective, observational trial evaluated VitaGraft Kidney’s dd-cfDNA diagnostic technology as a tool to discriminate between recurrent IgAN and ABMR.
  • In the study, VitaGraft Kidney demonstrated higher sensitivity and specificity for detection of ABMR over routine tests (eGFR, uACR, DSA).
  • Oncocyte has submitted its dd-cfDNA tests VitaGraft Kidney and Liver for Medicare reimbursement and expects its next feedback from Palmetto, which administers the MolDx Program, within 30 days.

World Kidney Day: A Bayer Survey Reveals Physicians Agree on Need for Earlier Testing and Increased Transparent Communication for People Diagnosed With Chronic Kidney Disease Associated With Type 2 Diabetes

Retrieved on: 
Thursday, March 9, 2023
Cardiology, Biotechnology, Pharmaceutical, Managed Care, General Health, Health, Diabetes, Other Health, Advance for NPs & PAs, PCP, Diagnosis, Nephrology, Microalbuminuria, Kidney, CKD, Chronic kidney disease, T2D, Face, Partnership, NPS, Patient, Bayer, World Kidney Day, Guideline, Practitioner, PAS, Type 2 diabetes, Glomerular filtration rate, Pharmaceutical industry, Nursing, Cardiorenal syndrome

Today, World Kidney Day, results from a survey designed to gain a broader understanding of the attitudes and challenges faced by healthcare professionals (HCPs) in diagnosing, managing and treating people with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) were announced.

Key Points: 
  • Today, World Kidney Day, results from a survey designed to gain a broader understanding of the attitudes and challenges faced by healthcare professionals (HCPs) in diagnosing, managing and treating people with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) were announced.
  • The survey was executed by Bayer and fielded in partnership with MedSurvey, a leading medical market research company.
  • Findings from the survey, which queried a total of 1,000 respondents made up of nephrologists, primary care physicians (PCPs), nurse practitioners (NPs) and physician assistants (PAs), revealed that HCPs believe care can be improved, with a collective acknowledgement that people with T2D need to be tested for CKD earlier and more often, despite results showing that guideline-driven tests to monitor for CKD and its progression, like urine albumin-creatinine ratio (uACR), a urine test to assess kidney function, are underutilized.1,2
    When people are diagnosed with CKD associated with T2D, they often receive initial care from their PCP and are referred to a nephrologist (kidney specialists), only after their CKD has progressed.3
    Survey results also revealed that PCPs and nephrologists have differing opinions on who should be the lead medical professional coordinating treatment and management, resulting in a significant number of patients not being referred to nephrologists earlier, despite the majority of HCPs surveyed agreeing that nephrologists need to be brought in sooner.1
    “Research has shown that co-management between a primary care physician and a nephrologist is associated with improved quality of care, delayed dialysis and more frequent testing, but we wanted to more deeply understand some of the challenges the treatment team faced in an effort to incite conversations about how we can improve on them,” said German Guerrero, M.D., Executive Medical Director, Cardiorenal, Bayer.4 “At Bayer, we are working to ensure people with chronic kidney disease associated with type 2 diabetes receive optimal care that ultimately leads to earlier diagnosis and treatment and better outcomes.”
    The majority of HCPs surveyed (80% PCPs, 88% nephrologists, 88% NPs/PAs) agree the medical community could do better and diagnose CKD in people with T2D earlier1
    While a majority of HCPs are using estimated glomerular filtration rate (eGFR) blood tests to assess kidney function at least once every few months (62% PCPs, 80% nephrologists, 77% NPs/PAs), uACR tests are significantly underutilized (30% PCPs, 57% nephrologists, 38% NPs/PAs), clashing with guideline recommendations to test more frequently1
    The vast majority of HCPs (77% PCPs, 90% nephrologists, 89% NPs/PAs) agree nephrologists need to be brought in earlier, yet 88% of PCPs may choose not to refer people with CKD to a nephrologist; the top reasons include1:
    The top challenges HCPs face when co-managing patients include1:
    “These findings reinforce the importance of our commitment to identifying resources and programs aimed at better understanding the real-world management of chronic kidney disease and expanding screening and early care management,” said Dr. Guerrero.
  • “Together—with healthcare professionals and the broader kidney community—we have an opportunity to improve the diagnosis and management of chronic kidney disease to truly advance care.”

The National Kidney Foundation and Healthy.io partner to Increase Access to Testing for Detection of Kidney Disease

Retrieved on: 
Wednesday, March 8, 2023
Healthy.io, MD, NKF, Kidney failure, National Kidney Foundation, Kidney disease, Dialysis, CKD, Chronic kidney disease, Hypertension, Partnership, World Kidney Day, African Americans, Patient, Risk, Disease, ESRD, Diabetes, Transport, Urine, ACR, FDA, EGFR, Microalbuminuria, Glomerular filtration rate, Pharmaceutical industry, Multiple minute digitate hyperkeratosis

BOSTON, March 8, 2023 /PRNewswire/ -- The National Kidney Foundation (NKF), a non-profit health organization dedicated to the awareness, prevention, and treatment of kidney disease, and Healthy.io, the global leader in transforming the smartphone camera into a clinical-grade medical device, today announced a new effort to promote detection of chronic kidney disease (CKD). Through their partnership, the NKF and Healthy.io will offer Healthy.io's Minuteful Kidney™ at-home kidney test, free of charge, to people who are at risk for kidney disease. 

Key Points: 
  • Through their partnership, the NKF and Healthy.io will offer Healthy.io's Minuteful Kidney™ at-home kidney test, free of charge, to people who are at risk for kidney disease.
  • "This is particularly concerning when it comes to annual urine testing for kidney disease.
  • campaign aims to raise awareness of the importance of early kidney disease detection," said Joseph Vassalotti, MD, Chief Medical Officer of the National Kidney Foundation.
  • Working to promote kidney health equity for all and increasing access to early detection are top priorities for NKF.

L-Nutra Reports on First-of-Its Kind Study Showing That Fasting Nutrition Program Improves Metabolic Control and Slows Diabetic Kidney Disease in Type 2 Diabetes Patients

Retrieved on: 
Tuesday, June 21, 2022
Nutrition, Microalbuminuria, Journal, FMD, Safety, Technology, Human, CEO, Type 2 diabetes, Metabolism, Urine, Mediterranean diet, Program, Health, Volunteering, Harvard University, Kidney disease, Diabetic nephropathy, Joslin Diabetes Center, Endocrine Society, Insulin resistance, Patient, University Hospital Heidelberg, Longevity, Fasting, Diabetes, GLOBE, HOMA-IR, Pharmaceutical industry

Diabetic kidney disease is the leading cause of end-stage kidney complication in people with diabetes.

Key Points: 
  • Diabetic kidney disease is the leading cause of end-stage kidney complication in people with diabetes.
  • The investigators explored for the first time in a randomized controlled design the clinical impact of FMD in type 2 diabetes patients.
  • They showed that FMD is safe and well tolerated when accompanied by intensive diabetes care.
  • The study recruited 40 volunteers with type 2 diabetes who had protein in their urine (a sign of kidney disease).

Albumin & Creatinine Tests Market worth $2,103 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, January 14, 2021
Branches of biology, Renal physiology, Blood proteins, Creatinine, Guanidines, Metabolism, Serum albumin, Dipstick, ACR, Biology, Microalbuminuria

The dipsticks & kits products segment accounted for the largest share of the ACR Tests Market, by product segment, in 2019

Key Points: 
  • The dipsticks & kits products segment accounted for the largest share of the ACR Tests Market, by product segment, in 2019
    Based on product, the albumin and creatinine tests market is segmented into dipsticks & kits, analyzers, cartridges, and reagents & other consumables.
  • In 2019, the dipsticks & kits segment accounted for the largest share in this market.
  • The frequent purchase of these products compared to instruments like analyzers and cartridges and the increasing use of kit-based rapid techniques for albumin & creatinine tests drive market growth.
  • Based on type, the albumin & creatinine tests market is segmented into urine tests and blood & serum creatinine tests.

Albumin & Creatinine Tests Market worth $2,103 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, January 14, 2021
Branches of biology, Renal physiology, Blood proteins, Creatinine, Guanidines, Metabolism, Serum albumin, Dipstick, ACR, Biology, Microalbuminuria

The dipsticks & kits products segment accounted for the largest share of the ACR Tests Market, by product segment, in 2019

Key Points: 
  • The dipsticks & kits products segment accounted for the largest share of the ACR Tests Market, by product segment, in 2019
    Based on product, the albumin and creatinine tests market is segmented into dipsticks & kits, analyzers, cartridges, and reagents & other consumables.
  • In 2019, the dipsticks & kits segment accounted for the largest share in this market.
  • The frequent purchase of these products compared to instruments like analyzers and cartridges and the increasing use of kit-based rapid techniques for albumin & creatinine tests drive market growth.
  • Based on type, the albumin & creatinine tests market is segmented into urine tests and blood & serum creatinine tests.